Home › Companies › CIDARA THERAPEUTICS INC. › 2024-2025
At CIDARA THERAPEUTICS INC.'s 2 shareholder meetings in the 2024-2025 proxy season (held July 18, 2024 and June 18, 2025), 56 asset managers reported how they voted on 16 ballot items in their SEC Form N-PX filings, covering 309 separate fund positions. On the most widely held item of the season, voted at the meeting held June 18, 2025 — Approval, on an advisory basis, of the compensation of the Company's named executive officers… — CIDARA THERAPEUTICS INC.'s filing reports the proposal as approved, with 75% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CIDARA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CIDARA THERAPEUTICS INC.’s Form 8-K, filed June 20, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 18, 2025: 7 items on CIDARA THERAPEUTICS INC.’s Form 8-K, filed June 20, 2025: 3 elected · 4 approved.
Meeting of July 18, 2024: 9 items on CIDARA THERAPEUTICS INC.’s Form 8-K, filed July 18, 2024: 3 elected · 6 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025
Explore CIDARA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are CIDARA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. CIDARA THERAPEUTICS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jeffrey Stein, Ph.D. | 10,808,693 | -- | -- | 24,728 | 2,327,079 | 99.7% | Elected | — |
| Elect Director: Bonnie Bassler, Ph.D. | 8,180,884 | -- | -- | 2,652,537 | 2,327,079 | 76% | Elected | — |
| Elect Director: Ryan Spencer | 10,809,694 | -- | -- | 23,727 | 2,327,079 | 99.7% | Elected | — |
| 2. Approval of an Amendment to our Amended and Restated Certificate of Incorporation, as Amended, to Increase the Number of Authorized Shares of Common Stock | 13,042,275 | 97,601 | 20,624 | -- | -- | 99.2% | Approved | — |
| 3. Approval of the Amended 2024 Plan | 7,791,328 | 3,033,052 | 9,041 | -- | 2,327,079 | 72% | Approved | — |
| 4. Ratification of the Appointment of Independent Registered Public Accounting Firm | 13,144,234 | 13,752 | 2,514 | -- | -- | 99.8% | Approved | — |
| 5. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers | 8,077,470 | 2,745,374 | 10,577 | -- | 2,327,079 | 75% | Approved | — |
Source: CIDARA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 20, 2025 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Carin Canale-Theakston | 2,243,061 | -- | -- | 100,665 | 1,353,532 | 96% | Elected | — |
| Elect Director: James Merson, Ph.D. | 2,247,381 | -- | -- | 96,345 | 1,353,532 | 96% | Elected | — |
| Elect Director: Chrysa Mineo | 2,230,247 | -- | -- | 113,479 | 1,353,532 | 95% | Elected | — |
| 2. Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock | 2,357,192 | 392,875 | 39,413 | -- | -- | 86% | Approved | — |
| 3. Approval, for Purposes of Nasdaq Listing Rule 5635(b), of any Change of Control that May Result from the Issuance of Shares of the Company's Common Stock Upon the Conversion of the Series A Preferred Stock | 1,259,652 | 166,995 | 9,301 | -- | 1,353,532 | 88% | Approved | — |
| 4. Approval of the Company's 2024 Equity Incentive Plan | 2,072,549 | 264,206 | 6,971 | -- | 1,353,532 | 89% | Approved | — |
| 5. Ratification of the Selection of Independent Registered Public Accounting Firm | 3,501,365 | 63,475 | 132,418 | -- | -- | 98% | Approved | — |
| 6. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers | 2,174,835 | 155,452 | 13,439 | -- | 1,353,532 | 93% | Approved | — |
| 7. Approval of the Adjournment of the Annual Meeting, if Necessary, to Solicit Additional Proxies | 3,333,867 | 329,610 | 33,781 | -- | -- | 91% | Approved | — |
Source: CIDARA THERAPEUTICS INC., Form 8-K, filed with the SEC on July 18, 2024 — read the filing on EDGAR.
Each item below shows how the 56 asset managers that disclosed a CIDARA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held June 18, 2025.
Combines 2 wordings of this item as funds reported it.
76% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Bonnie Bassler, Ph.D.
CIDARA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Bonnie Bassler, Ph.D.”): 8,180,884 for, 2,652,537 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 76% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 336,840 for, 134,764 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 324,138 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 120,879 | Withhold |
| Fidelity | 7,644 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 7,299 | Withhold |
| American Century | 0 | 0 | 0 | 5,579 | Withhold |
| BlackRock | 3,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 726 | Withhold |
| Equitable | 556 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 221 | Withhold |
| Invesco | 0 | 0 | 0 | 60 | Withhold |
Meeting held June 18, 2025.
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Jeffrey Stein, Ph.D.
CIDARA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeffrey Stein, Ph.D.”): 10,808,693 for, 24,728 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 463,960 for, 7,644 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 324,138 | 0 | 0 | 0 | For |
| Aberdeen | 120,879 | 0 | 0 | 0 | For |
| Fidelity | 0 | 0 | 0 | 7,644 | Withhold |
| Northern Trust | 7,299 | 0 | 0 | 0 | For |
| American Century | 5,579 | 0 | 0 | 0 | For |
| BlackRock | 3,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Victory Capital | 726 | 0 | 0 | 0 | For |
| Equitable | 556 | 0 | 0 | 0 | For |
| John Hancock | 221 | 0 | 0 | 0 | For |
| Invesco | 60 | 0 | 0 | 0 | For |
Meeting held June 18, 2025.
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Ryan Spencer
CIDARA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ryan Spencer”): 10,809,694 for, 23,727 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 471,604 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 324,138 | 0 | 0 | 0 | For |
| Aberdeen | 120,879 | 0 | 0 | 0 | For |
| Fidelity | 7,644 | 0 | 0 | 0 | For |
| Northern Trust | 7,299 | 0 | 0 | 0 | For |
| American Century | 5,579 | 0 | 0 | 0 | For |
| BlackRock | 3,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Victory Capital | 726 | 0 | 0 | 0 | For |
| Equitable | 556 | 0 | 0 | 0 | For |
| John Hancock | 221 | 0 | 0 | 0 | For |
| Invesco | 60 | 0 | 0 | 0 | For |
Meeting held July 18, 2024.
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Carin Canale-Theakston
CIDARA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Carin Canale-Theakston”): 2,243,061 for, 100,665 withheld, per its Form 8-K filed July 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 141,987 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 119,862 | 0 | 0 | 0 | For |
| Fidelity | 13,814 | 0 | 0 | 0 | For |
| BlackRock | 6,815 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Equitable | 156 | 0 | 0 | 0 | For |
Meeting held July 18, 2024.
Combines 2 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: Chrysa Mineo
CIDARA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Chrysa Mineo”): 2,230,247 for, 113,479 withheld, per its Form 8-K filed July 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 140,647 for, 1,340 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 119,862 | 0 | 0 | 0 | For |
| Fidelity | 13,814 | 0 | 0 | 0 | For |
| BlackRock | 6,815 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,340 | Withhold |
| Equitable | 156 | 0 | 0 | 0 | For |
Meeting held July 18, 2024.
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Class III Directors: James Merson, Ph.D.
CIDARA THERAPEUTICS INC.’s own tally for this item (“Elect Director: James Merson, Ph.D.”): 2,247,381 for, 96,345 withheld, per its Form 8-K filed July 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 141,987 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 119,862 | 0 | 0 | 0 | For |
| Fidelity | 13,814 | 0 | 0 | 0 | For |
| BlackRock | 6,815 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Equitable | 156 | 0 | 0 | 0 | For |
Meeting held June 18, 2025.
99.2% Approved · of votes cast
Description as filed by funds: Amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the total number of authorized shares of Common Stock from 50,000,000 shares to 100,000,000 shares.
CIDARA THERAPEUTICS INC.’s own tally for this item (“2. Approval of an Amendment to our Amended and Restated Certificate of Incorporation, as Amended, to Increase the Number of Authorized Shares of Common Stock”): 13,042,275 for, 97,601 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval of an Amendment to our Amended and Restated Certificate of Incorporation, as Amended, to Increase the Number of Authorized Shares of Common Stock The Company's stockholders approved the Certificate of Amendment to increase the total number of authorized shares of Common Stock from 50,000,0…”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 471,604 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 324,138 | 0 | 0 | 0 | For |
| Aberdeen | 120,879 | 0 | 0 | 0 | For |
| Fidelity | 7,644 | 0 | 0 | 0 | For |
| Northern Trust | 7,299 | 0 | 0 | 0 | For |
| American Century | 5,579 | 0 | 0 | 0 | For |
| BlackRock | 3,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Victory Capital | 726 | 0 | 0 | 0 | For |
| Equitable | 556 | 0 | 0 | 0 | For |
| John Hancock | 221 | 0 | 0 | 0 | For |
| Invesco | 60 | 0 | 0 | 0 | For |
Meeting held July 18, 2024.
Combines 2 wordings of this item as funds reported it.
86% Approved · of votes cast
Description as filed by funds: Amendment of the Company's Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of Common Stock from 20,000,000 shares to 50,000,000
CIDARA THERAPEUTICS INC.’s own tally for this item (“2. Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock”): 2,357,192 for, 392,875 against — passed, per its Form 8-K filed July 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval of an Amendment to our Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock The Company's stockholders approved the Certificate of Amendment to increase the total number of authorized shares of Common Stock from 20,000,000 shares to …”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 141,987 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 119,862 | 0 | 0 | 0 | For |
| Fidelity | 13,814 | 0 | 0 | 0 | For |
| BlackRock | 6,815 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Equitable | 156 | 0 | 0 | 0 | For |
Meeting held July 18, 2024.
Combines 2 wordings of this item as funds reported it.
88% Approved · of votes cast
Description as filed by funds: Approval, for purposes of Nasdaq Listing Rule 5635(b), of any change of control that may result from the issuance of shares of the Company's Common Stock upon the conversion of the Series A Preferred Stock
CIDARA THERAPEUTICS INC.’s own tally for this item (“3. Approval, for Purposes of Nasdaq Listing Rule 5635(b), of any Change of Control that May Result from the Issuance of Shares of the Company's Common Stock Upon the Conversion of the Series A Preferred Stock”): 1,259,652 for, 166,995 against — passed, per its Form 8-K filed July 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval, for Purposes of Nasdaq Listing Rule 5635(b), of any Change of Control that May Result from the Issuance of Shares of the Company's Common Stock Upon the Conversion of the Series A Preferred Stock The Company's stockholders approved, for purposes of Nasdaq Listing Rule 5635(b), any change …”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 141,987 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 119,862 | 0 | 0 | 0 | For |
| Fidelity | 13,814 | 0 | 0 | 0 | For |
| BlackRock | 6,815 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Equitable | 156 | 0 | 0 | 0 | For |
Meeting held July 18, 2024.
Combines 2 wordings of this item as funds reported it.
91% Approved · of votes cast
Description as filed by funds: Approval of the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 2 or 3
CIDARA THERAPEUTICS INC.’s own tally for this item (“7. Approval of the Adjournment of the Annual Meeting, if Necessary, to Solicit Additional Proxies”): 3,333,867 for, 329,610 against — passed, per its Form 8-K filed July 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 7: Approval of the Adjournment of the Annual Meeting, if Necessary, to Solicit Additional Proxies The Company's stockholders approved the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 141,987 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 119,862 | 0 | 0 | 0 | For |
| Fidelity | 13,814 | 0 | 0 | 0 | For |
| BlackRock | 6,815 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Equitable | 156 | 0 | 0 | 0 | For |
Meeting held June 18, 2025.
72% Approved · of votes cast
Description as filed by funds: Approval of an amendment to the Company's 2024 Equity Incentive Plan.
CIDARA THERAPEUTICS INC.’s own tally for this item (“3. Approval of the Amended 2024 Plan”): 7,791,328 for, 3,033,052 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval of the Amended 2024 Plan The Company's stockholders approved the Amended 2024 Plan.”
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 11,422 for, 460,182 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 324,138 | 0 | 0 | Against |
| Aberdeen | 0 | 120,879 | 0 | 0 | Against |
| Fidelity | 7,644 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 7,299 | 0 | 0 | Against |
| American Century | 0 | 5,579 | 0 | 0 | Against |
| BlackRock | 3,162 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 1,340 | 0 | 0 | Against |
| Victory Capital | 0 | 726 | 0 | 0 | Against |
| Equitable | 556 | 0 | 0 | 0 | For |
| John Hancock | 0 | 221 | 0 | 0 | Against |
| Invesco | 60 | 0 | 0 | 0 | For |
Meeting held July 18, 2024.
Combines 2 wordings of this item as funds reported it.
89% Approved · of votes cast
CIDARA THERAPEUTICS INC.’s own tally for this item (“4. Approval of the Company's 2024 Equity Incentive Plan”): 2,072,549 for, 264,206 against — passed, per its Form 8-K filed July 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval of the Company's 2024 Equity Incentive Plan The Company's stockholders approved the Company's 2024 Equity Incentive Plan.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 140,647 for, 1,340 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 119,862 | 0 | 0 | 0 | For |
| Fidelity | 13,814 | 0 | 0 | 0 | For |
| BlackRock | 6,815 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 1,340 | 0 | 0 | Against |
| Equitable | 156 | 0 | 0 | 0 | For |
Meeting held June 18, 2025.
Combines 5 wordings of this item as funds reported it.
75% Approved · of votes cast
Description as filed by funds: Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in: the proxy statement.
CIDARA THERAPEUTICS INC.’s own tally for this item (“5. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 8,077,470 for, 2,745,374 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement for the Annual Meeting.”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 324,138 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 120,879 | 0 | 0 | Against |
| Fidelity | 0 | 7,644 | 0 | 0 | Against |
| Northern Trust | 0 | 7,299 | 0 | 0 | Against |
| American Century | 0 | 5,579 | 0 | 0 | Against |
| BlackRock | 0 | 3,162 | 0 | 0 | Against |
| Charles Schwab | 0 | 1,340 | 0 | 0 | Against |
| Victory Capital | 0 | 726 | 0 | 0 | Against |
| Equitable | 0 | 556 | 0 | 0 | Against |
| John Hancock | 0 | 221 | 0 | 0 | Against |
| Invesco | 0 | 60 | 0 | 0 | Against |
Fund voting reports, all 11 managers: 324,138 for, 147,466 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 1,922,850 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 1,182,752 | 0 | 0 | 0 | For |
| TCG Crossover Management, LLC | 1,005,901 | 0 | 0 | 0 | For |
| Point72 | 0 | 999,394 | 0 | 0 | Against |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 981,100 | 0 | 0 | Against |
| VR Adviser, LLC | 657,548 | 0 | 0 | 0 | For |
| BVF INC/IL | 557,061 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 0 | 379,546 | 0 | 0 | Against |
| Aberdeen | 0 | 120,879 | 0 | 0 | Against |
| Renaissance | 0 | 46,623 | 0 | 0 | Against |
| Goldman Sachs | 34,970 | 0 | 0 | 0 | For |
| OMERS ADMINISTRATION Corp | 0 | 28,600 | 0 | 0 | Against |
| BlackRock | 0 | 26,230 | 0 | 0 | Against |
| Citadel | 19,477 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0 | 19,445 | 0 | 0 | Against |
| ADAR1 Capital Management, LLC | 0 | 18,938 | 0 | 0 | Against |
| Northern Trust | 0 | 16,154 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 11,783 | 0 | 0 | Against |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 10,500 | 0 | 0 | Against |
| American Century | 0 | 5,579 | 0 | 0 | Against |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 5,172 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 0 | 4,157 | 0 | 0 | Against |
| State Street | 4,085 | 36 | 0 | 0 | For |
| CAPSTONE INVESTMENT ADVISORS, LLC | 0 | 3,204 | 0 | 0 | Against |
| Hudson Bay Capital Management LP | 0 | 2,844 | 0 | 0 | Against |
Institutional-manager reports, all 41 managers: 5,388,409 for, 2,684,274 against. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held July 18, 2024.
Combines 3 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement.
CIDARA THERAPEUTICS INC.’s own tally for this item (“6. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 2,174,835 for, 155,452 against — passed, per its Form 8-K filed July 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement for the Annual Meeting.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 119,862 | 0 | 0 | 0 | For |
| Fidelity | 13,814 | 0 | 0 | 0 | For |
| BlackRock | 6,815 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Equitable | 156 | 0 | 0 | 0 | For |
Fund voting reports, all 5 managers: 141,987 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 703,080 | 0 | 0 | 0 | For |
| BVF INC/IL | 343,055 | 0 | 0 | 0 | For |
| 5AM Venture Management, LLC | 56,725 | 0 | 0 | 0 | For |
| Point72 | 34,998 | 0 | 0 | 0 | For |
| Renaissance | 27,325 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 16,411 | 0 | 0 | 0 | For |
| US BANK NATIONAL ASSOCIATION | 13,103 | 0 | 0 | 0 | For |
| State Street | 11,576 | 0 | 0 | 0 | For |
| BlackRock | 11,519 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 10,500 | 0 | 0 | 0 | For |
| Northern Trust | 5,185 | 0 | 0 | 0 | For |
| BLAIR WILLIAM & CO/IL | 5,000 | 0 | 0 | 0 | For |
| Citadel | 2,825 | 0 | 0 | 0 | For |
| Prudential/PGIM | 2,100 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | 1,300 | 0 | 0 | 0 | For |
| Two Sigma | 976 | 0 | 0 | 0 | For |
| Vanguard | 893 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 600 | 0 | 0 | 0 | For |
| Manchester Capital Management LLC | 470 | 0 | 0 | 0 | For |
| Pacifica Partners Inc. | 400 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 379 | 0 | 0 | 0 | For |
| Cerity Partners LLC | 350 | 0 | 0 | 0 | For |
| McCollum Christoferson Group LLC | 225 | 0 | 0 | 0 | For |
| Stonegate Investment Group, LLC | 150 | 0 | 0 | 0 | For |
Institutional-manager reports, all 30 managers: 1,250,758 for. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held June 18, 2025.
99.8% Approved · of votes cast
Description as filed by funds: Ratification of the appointment of Ernst & Young LLP by the Audit Committee of the Board to serve as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025.
CIDARA THERAPEUTICS INC.’s own tally for this item (“4. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 13,144,234 for, 13,752 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of the Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP by the Audit Committee of the Company's Board of Directors to serve as the Company's independent registered public accounting firm for the fiscal…”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 11 asset managers below reported 471,604 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 324,138 | 0 | 0 | 0 | For |
| Aberdeen | 120,879 | 0 | 0 | 0 | For |
| Fidelity | 7,644 | 0 | 0 | 0 | For |
| Northern Trust | 7,299 | 0 | 0 | 0 | For |
| American Century | 5,579 | 0 | 0 | 0 | For |
| BlackRock | 3,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Victory Capital | 726 | 0 | 0 | 0 | For |
| Equitable | 556 | 0 | 0 | 0 | For |
| John Hancock | 221 | 0 | 0 | 0 | For |
| Invesco | 60 | 0 | 0 | 0 | For |
Meeting held July 18, 2024.
Combines 2 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: Ratification of the selection of Ernst & Young LLP by the Audit Committee of the Board to serve as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024
CIDARA THERAPEUTICS INC.’s own tally for this item (“5. Ratification of the Selection of Independent Registered Public Accounting Firm”): 3,501,365 for, 63,475 against — passed, per its Form 8-K filed July 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Company's Board of Directors to serve as the Company's independent registered public accounting firm for the fiscal yea…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 5 asset managers below reported 141,987 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 119,862 | 0 | 0 | 0 | For |
| Fidelity | 13,814 | 0 | 0 | 0 | For |
| BlackRock | 6,815 | 0 | 0 | 0 | For |
| Charles Schwab | 1,340 | 0 | 0 | 0 | For |
| Equitable | 156 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 12,969,823 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.50% |
| 2 | Aberdeen | 0.93% |
| 3 | Fidelity | 0.06% |
| 4 | Northern Trust | 0.06% |
| 5 | American Century | 0.04% |
| 6 | BlackRock | 0.02% |
| 7 | Charles Schwab | 0.01% |
| 8 | Victory Capital | <0.01% |
| 9 | Equitable | <0.01% |
| 10 | John Hancock | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vivo Capital, LLC | 14.83% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.12% |
| 3 | TCG Crossover Management, LLC | 7.76% |
| 4 | Point72 | 7.71% |
| 5 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.56% |
| 6 | VR Adviser, LLC | 5.07% |
| 7 | BVF INC/IL | 4.30% |
| 8 | Vestal Point Capital, LP | 2.93% |
| 9 | Aberdeen | 0.93% |
| 10 | Renaissance | 0.36% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BCLS Fund III Investments, LP | 10.13% | DEF14A |
| Canaan XII L.P. | 10.13% | DEF14A |
| Entities Affiliated with Biotechnology Value Fund, L.P. | 9.95% | DEF14A |
| RA Capital Healthcare Fund, L.P. | 9.80% | DEF14A |
| Entities Affiliated with Venrock Healthcare Capital Partners | 9.51% | DEF14A |
| BVF PARTNERS L P/IL | 9.17% | 13G |
| Adage Capital Management, L.P. | 8.48% | 13G |
| TCG Crossover Fund II, LP | 7.76% | DEF14A |
| Entities Affiliated with Point72 Asset Management, L.P. | 7.71% | DEF14A |
| Paradigm BioCapital Advisors LP | 7.41% | 13G |
Percentages above are of 12,969,823 shares outstanding, as reported by CIDARA THERAPEUTICS INC. on its Form 10-Q dated May 5, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CIDARA THERAPEUTICS INC.’s 10-Q dated May 5, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
CIDARA THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page).
proxyvotesnow.com, “CIDARA THERAPEUTICS INC. 2024-2025 Annual Meetings: Vote Results”, https://proxyvotesnow.com/company/cidara-therapeutics-inc/2025 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.